Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : The OTCBB Garbage Dump -- Ignore unavailable to you. Want to Upgrade?

To: Jetta who wrote (2344)	9/22/1999 3:27:00 PM
From: Wayne Rumball	Read Replies (1) \| Respond to of 2942

LXXN looks like big news, hold on to your hat

To: Jetta who wrote (2344)	9/22/1999 3:33:00 PM
From: Wayne Rumball	Read Replies (1) \| Respond to of 2942

TULSA, Okla.--(BW HealthWire)--Sept. 22, 1999--Lexon, Inc. (OTC BB: LXXN) today announced the development of a bioassay test for the ebaf protein. Lexon's Ebaf Assay(TM) prototype utilizes a standard bioassay system available to most clinical laboratories. This bioassay form of the Ebaf Assay(TM) actually measures the amount of biologically active ebaf protein present. The bioassay can potentially be used not only to detect the presence of ebaf, but also to quantitate the amount of ebaf in cancer tissue and in the serum of cancer patients. The ebaf protein appears in the blood of patients with colon cancer and in some forms of ovarian and testicular cancer and detection of ebaf in the blood can be used as a screening test. The ebaf protein can be detected with complex laboratory equipment, and now with the newly developed bioassay. Lexon will subsequently develop a test kit, so that any clinical laboratory can screen blood for colon cancer. Lexon believes that the test, once past the FDA approval process, will be quick, inexpensive, and widely available. Lexon has sponsored and funded the continuing research and development of the cancer screening test at North Shore University Hospital in Manhasset, New York, under the direction of Dr. Siamak Tabibzadeh, the developer of the Ebaf Assay(TM). Dr. Tabibzadeh currently serves as Chief of Experimental Pathology at North Shore. The completion of this phase of the development allows for the initiation of preclinical patient testing to gather data for the FDA approval process. Gifford Mabie, President of Lexon, said, "We are gratified to have participated in the development of the first and only blood test for the early detection of colon cancer. This test is a major clinical innovation!" This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including, without limitation, the ability of Lexon, Inc. to accomplish its stated plan of business. Although Lexon believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by Lexon or any other person that the objectives and plans of Lexon will be achieved. For more information, visit the Lexon website: www.lexoninc.com, or see contact below. --30--SH/dx* CONTACT: Morgan-Phillips, Inc. 800/770-4856 918/250-8028 www.Morgan-Phillips.com